Anebulo Pharmaceuticals, Inc. (ANEB)
OTCMKTS · Delayed Price · Currency is USD
0.3200
-0.0050 (-1.54%)
At close: Sep 28, 2026
Anebulo Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 9.04 | 11.63 | 3.09 | 11.25 | 14.55 | 19.99 |
Cash & Short-Term Investments | 9.04 | 11.63 | 3.09 | 11.25 | 14.55 | 19.99 |
Cash Growth | -39.72% | 275.80% | -72.49% | -22.69% | -27.21% | 560.69% |
Other Receivables | 0.06 | 0.07 | - | - | - | - |
Receivables | 0.06 | 0.07 | - | - | - | - |
Prepaid Expenses | 0.18 | 0.26 | 0.41 | 0.42 | 1.03 | 1.67 |
Total Current Assets | 9.27 | 11.96 | 3.51 | 11.67 | 15.58 | 21.65 |
Other Long-Term Assets | 0.15 | 0.18 | 0.57 | - | - | - |
Total Assets | 9.42 | 12.15 | 4.07 | 11.67 | 15.58 | 21.65 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 0.55 | 0.22 | 0.16 | 0.53 | 0.38 | 0.11 |
Accrued Expenses | 0.93 | 0.26 | 0.1 | 0.53 | 0.13 | 0.13 |
Total Current Liabilities | 1.49 | 0.49 | 0.26 | 1.07 | 0.51 | 0.24 |
Total Liabilities | 1.49 | 0.49 | 0.26 | 1.07 | 0.51 | 0.24 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 |
Additional Paid-In Capital | 85.94 | 85.51 | 69.19 | 67.78 | 60.51 | 60.03 |
Retained Earnings | -78.05 | -73.89 | -65.4 | -57.2 | -45.47 | -38.64 |
Total Common Equity | 7.94 | 11.66 | 3.81 | 10.6 | 15.07 | 21.41 |
Shareholders' Equity | 7.94 | 11.66 | 3.81 | 10.6 | 15.07 | 21.41 |
Total Liabilities & Equity | 9.42 | 12.15 | 4.07 | 11.67 | 15.58 | 21.65 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Cash (Debt) | 9.04 | 11.63 | 3.09 | 11.25 | 14.55 | 19.99 |
Net Cash Growth | -39.72% | 275.80% | -72.49% | -22.69% | -27.21% | 607.78% |
Net Cash Per Share | 0.22 | 0.34 | 0.12 | 0.45 | 0.62 | 1.47 |
Filing Date Shares Outstanding | 40.78 | 41.08 | 25.93 | 25.63 | 23.37 | 23.34 |
Total Common Shares Outstanding | 41.08 | 41.08 | 25.93 | 25.63 | 23.34 | 23.34 |
Working Capital | 7.79 | 11.47 | 3.25 | 10.6 | 15.07 | 21.41 |
Book Value Per Share | 0.19 | 0.28 | 0.15 | 0.41 | 0.65 | 0.92 |
Tangible Book Value | 7.94 | 11.66 | 3.81 | 10.6 | 15.07 | 21.41 |
Tangible Book Value Per Share | 0.19 | 0.28 | 0.15 | 0.41 | 0.65 | 0.92 |